Explore groundbreaking studies, clinical trial updates, and emerging technologies shaping the future of cancer treatment.
Discover how the iFCG regimen is transforming first-line treatment for IGHV-mutated CLL patients without Del(17p)/TP53 mutation through targeted, time-limited therapy.